How Does Treace Medical Concepts Company Actually Work?

Lapiplasty is a patented surgical system that includes implants, instruments, and a defined surgical method to correct the unstable first tarsometatarsal joint in three planes rather than shaving the bunion bump. FDA-cleared as an orthopedic device, the system targets recurrence reduction and improved alignment with data showing lower revision rates versus traditional osteotomies in published studies.

Adductoplasty addresses midfoot deformity components; Nanoplasty and Percuplasty are minimally invasive surgery (MIS) tool suites for smaller incisions and faster recovery. These extend addressable procedures into the high-volume osteotomy segment that comprises roughly 70% of U.S. bunion surgeries.

Customers include orthopedic and podiatric surgeons, hospital systems, outpatient surgery centers, and patients among the ~1.1 million annual U.S. surgical bunion candidates. Treace Medical Concepts also sells to training and distribution partners that scale surgeon adoption and device procurement.

Surgeons gain a reproducible protocol and instrument set aimed at correcting the anatomical cause of bunions, reducing recurrence and revisions; hospitals get device-driven revenue and shorter stays for MIS options; patients see improved alignment and recovery metrics reported in clinical trials.

Adoption is driven by outcomes-focused evidence, a certification training program for surgeons, and a bundled implant-plus-instrument model that fits a medical device business model aiming for recurring implant sales and service revenue. Treace's IP portfolio and procedural training make Lapiplasty harder to replace than standalone implants.

By 2025 Treace Medical Concepts targets conversion of a meaningful share of the ~1.1 million annual U.S. bunion surgery candidates, focusing first on the ~70% osteotomy segment and expanding via MIS offerings and training programs to grow procedure volumes and implant utilization. Read more on company ownership and background at Who Owns Treace Medical Concepts Company

Sales of single-use Lapiplasty surgical kits and the corresponding permanent implants are the primary revenue source, because each procedure consumes both a kit and at least one proprietary implant that cannot be easily substituted.

Secondary income comes from surgeon training programs, instrument trays, ancillary disposables, and limited service contracts tied to surgeon adoption and device support.

Treace Medical Concepts prices kits and implants as one-time procedure purchases with higher-margin implants sold repeatedly as procedural volume grows; the model is razor-razorblade rather than subscription-based.

The main driver is surgeon adoption of Lapiplasty (procedure volume and repeat implant use); pricing mix shifts toward lower-priced kits can compress near-term revenue despite stable margins.

Treace Medical Concepts benefits from a large intellectual property portfolio that protects Lapiplasty technology and limits fast-copying of its bunion correction device, supporting sustained pricing power and clinical preference among certified surgeons.

Certification programs create deep surgeon loyalty and procedural uptake; once certified, surgeons are more likely to prefer Lapiplasty over traditional bunion surgery, raising lifetime device revenue per surgeon.

Despite improved cash efficiency-cash usage fell by 46 percent to $27.3 million in 2025-the company continues to rely on a $115 million credit facility to fund operations while absorbing losses.

Model durability hinges on restoring revenue growth via new product launches and managing a shift to lower-priced product mix; positive adjusted EBITDA of $6.2 million in Q4 2025 is encouraging but not decisive.